thiazolidines has been researched along with Non-alcoholic Fatty Liver Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Akahane, T; Fujinaga, Y; Furukawa, M; Kaji, K; Kawaratani, H; Kaya, D; Kitade, M; Kitagawa, K; Mitoro, A; Moriya, K; Nakanishi, K; Namisaki, T; Noguchi, R; Ozutsumi, T; Saikawa, S; Sato, S; Sawada, Y; Shimozato, N; Takaya, H; Tsuji, Y; Yoshiji, H | 1 |
| Li, Y; Liu, S; Nie, Y; Sun, K; Wang, H; Wang, X; Zhou, Y | 1 |
| Ichikawa, T; Kohno, S; Nakao, K; Onitsuka, Y; Takeshima, F | 1 |
| Ishii, Y; Ito, T; Kashimura, A; Saito, S; Sameshima, A; Sasahara, M; Sasaoka, T; Sawakawa, K; Tsuneki, H; Wada, T; Yonezawa, R | 1 |
| Ideta, T; Kochi, T; Miyazaki, T; Moriwaki, H; Sakai, H; Shimizu, M; Shirakami, Y | 1 |
| Asai, A; Fukunishi, S; Higuchi, K; Nakamura, K; Ohama, H; Tsuchimoto, Y; Tsuda, Y; Yokohama, K | 1 |
6 other study(ies) available for thiazolidines and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Topics: Animals; Cadherins; Canagliflozin; Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytokines; Disease Progression; DNA Damage; Drug Synergism; Hepatic Stellate Cells; Human Umbilical Vein Endothelial Cells; Humans; Lipid Peroxidation; Liver Cirrhosis; Liver Neoplasms; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Pyrazoles; Rats; Rats, Inbred Strains; Thiazolidines; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2020 |
NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Male; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Thiazolidines; Thiones; Triglycerides | 2021 |
Estimation of visceral fat and fatty liver disease using ultrasound in patients with diabetes.
Topics: Aged; Biguanides; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Diet, Western; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intra-Abdominal Fat; Japan; Logistic Models; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Prevalence; Thiazolidines; Ultrasonography; Waist Circumference | 2014 |
Teneligliptin improves metabolic abnormalities in a mouse model of postmenopausal obesity.
Topics: Aging; Animals; Behavior, Animal; Body Temperature Regulation; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Energy Metabolism; Female; Intra-Abdominal Fat; Liver; Macrophages; Mice, Inbred C57BL; Motor Activity; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Ovariectomy; Panniculitis; Pyrazoles; Thiazolidines | 2015 |
The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
Topics: AMP-Activated Protein Kinases; Animals; Biomarkers; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Enzyme Activation; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Phosphorylation; Pyrazoles; Signal Transduction; Thiazolidines; Triglycerides | 2015 |
A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice.
Topics: Animals; Dietary Carbohydrates; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fructose; Male; Mice; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrazoles; Thiazolidines | 2017 |